

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Ogier, JM;Gao, Y;Dunne, EM;Wilson, MA;Ranganathan, SC;Tesch, GH;Nikolic Paterson, DJ;Dabdoub, A;Burt, RA;Nayagam, BA;Lockhart, PJ

Title:

ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death

Date:

2022-05-01

Citation:

Ogier, J. M., Gao, Y., Dunne, E. M., Wilson, M. A., Ranganathan, S. C., Tesch, G. H., Nikolic Paterson, D. J., Dabdoub, A., Burt, R. A., Nayagam, B. A. & Lockhart, P. J. (2022). ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death. *Journal of Molecular Medicine*, 100 (5), pp.797-813. <https://doi.org/10.1007/s00109-022-02188-1>.

Persistent Link:

<https://hdl.handle.net/11343/310645>

License:

CC BY



ORIGINAL ARTICLE

ASK1 is a novel molecular target for preventing aminoglycoside-induced hair cell death

Jacqueline M. Ogier^{1,2,3} · Yujing Gao^{1,2} · Eileen M. Dunne^{2,4} · Michael A. Wilson¹ · Sarath C. Ranganathan^{2,5,6} · Gregory H. Tesch⁷ · David J. Nikolic Paterson⁷ · Alain Dabdoub³ · Rachel A. Burt¹ · Bryony A. Nayagam^{8,9} · Paul J. Lockhart^{1,2}

Received: 9 June 2021 / Revised: 7 February 2022 / Accepted: 3 March 2022 / Published online: 26 April 2022
© The Author(s) 2022, corrected publication 2022

Abstract

Aminoglycoside antibiotics are lifesaving medicines, crucial for the treatment of chronic or drug resistant infections. However, aminoglycosides are toxic to the sensory hair cells in the inner ear. As a result, aminoglycoside-treated individuals can develop permanent hearing loss and vestibular impairment. There is considerable evidence that reactive oxygen species (ROS) production and the subsequent phosphorylation of c-Jun N-terminal kinase (JNK) and P38 mitogen-activated protein kinase (P38) drives apoptosis in aminoglycoside-treated hair cells. However, treatment strategies that directly inhibit ROS, JNK, or P38 are limited by the importance of these molecules for normal cellular function. Alternatively, the upstream regulator apoptosis signal-regulating kinase 1 (ASK1/MAP3K5) is a key mediator of ROS-induced JNK and P38 activation under pathologic but not homeostatic conditions. We investigated ASK1 as a mediator of drug-induced hair cell death using cochlear explants from *Ask1* knockout mice, demonstrating that *Ask1* deficiency attenuates neomycin-induced hair cell death. We then evaluated pharmacological inhibition of ASK1 with GS-444217 as a potential otoprotective therapy. GS-444217 significantly attenuated hair cell death in neomycin-treated explants but did not impact aminoglycoside efficacy against *P. aeruginosa* in the broth dilution test. Overall, we provide significant pre-clinical evidence that ASK1 inhibition represents a novel strategy for preventing aminoglycoside ototoxicity.

Key messages

- ASK1 is an upstream, redox-sensitive regulator of P38 and JNK, which are known mediators of hair cell death.
- *Ask1* knockout does not affect hair cell development in vivo, but significantly reduces aminoglycoside-induced hair cell death in vitro.
- A small-molecule inhibitor of ASK1 attenuates neomycin-induced hair cell death, and does not impact antibiotic efficacy in vitro.
- ASK1 may be a novel molecular target for preventing aminoglycoside-induced hearing loss.

Keywords Hair cell · Ototoxic · MAP3K5 · p38 · JNK · Hearing

✉ Jacqueline M. Ogier
Jacqueline.ogier@sri.utoronto.ca

¹ Bruce Lefroy Centre, Murdoch Children's Research Institute, Parkville, VIC, Australia

² Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia

³ Sunnybrook Research Institute, Toronto, ON, Canada

⁴ Pneumococcal Research Group, Murdoch Children's Research Institute, Parkville, VIC, Australia

⁵ Infection and Immunity, Murdoch Children's Research Institute, Parkville, VIC, Australia

⁶ Department of Respiratory Medicine, The Royal Children's Hospital, Parkville, VIC, Australia

⁷ Department of Nephrology, Monash Health and Monash University Centre for Inflammatory Diseases, Clayton, VIC, Australia

⁸ Department of Anatomy and Neuroscience, The University of Melbourne, Parkville, Australia

⁹ Department of Audiology and Speech Pathology, The University of Melbourne, Parkville, VIC, Australia

Introduction

Aminoglycoside antibiotics are used for serious or drug resistant infections of the respiratory tract, urinary tract, central nervous system or intra-abdominal organs, as well as endocarditis or sepsis (in adults and neonates), and prophylactically during and post-surgery. Aminoglycoside therapies preserve life; however, negative side effects are associated with their use. Careful dosing and monitoring regimens limit toxic outcomes, including encephalopathy, neuromuscular blockade, and nephrotoxicity [1]. However, ototoxicity (toxic outcomes relating to the ear) remains a persistent problem.

Aminoglycoside ototoxicity predominantly manifests as irreversible damage to the sensory hair cells (HCs) of the cochlea and vestibular apparatus. Therefore, aminoglycoside-treated individuals can experience permanent damage to their hearing and/or balance. The reported prevalence of aminoglycoside-induced ototoxic outcomes is variable (Table 1). Nevertheless, for those affected, ototoxicity has a profound effect on their quality of life [2, 3]. Currently, no treatment exists for the prevention of aminoglycoside-induced ototoxicity. Instead, clinical practice aims to minimise or avoid aminoglycoside use. However, an alternate therapy is not always feasible and a single aminoglycoside treatment can cause permanent damage to the inner ear [4]. Therefore, research efforts have focused on elucidating the mechanisms underlying aminoglycoside-induced HC death, to identify therapeutic targets to mitigate ototoxicity. These studies have established that HCs are susceptible to aminoglycoside toxicity, due to the abundance of HC specific mechano-electro-transduction (MET) channels that facilitate rapid aminoglycoside entry into the cell [5, 6]. Once the aminoglycoside has entered the HC, it targets and damages the mitochondrial ribosome, preventing mitochondrial protein synthesis.

Aminoglycoside-induced mitochondrial damage is linked with the drugs' antibiotic mechanism. Specifically, aminoglycosides bind to the A-site on the 16S ribosomal RNA of the 30S ribosome, inhibiting bacterial protein synthesis and killing the bacteria [7]. Shared ancestry between mitochondria and bacteria means that the mitochondrial ribosome is similar to the bacterial ribosome, and therefore susceptible to aminoglycoside binding. Aminoglycoside-induced disruption of mitochondrial protein synthesis is subsequently detected by innate cellular monitoring systems, initiating cell signalling cascades that result in HC death.

Cell death pathways are not well-defined in the inner ear. However, it is known that excessive mitochondrial ROS production and subsequent cellular oxidative stress is a key aspect of the process [8–10]. As a result, research

aiming to mitigate ototoxicity has predominantly focused on antioxidant compounds, with equivocal and often conflicting outcomes [11]. These studies have not translated to changes in medical care, and in some cases, antioxidant use was associated with serious side effects, such as bleeding, pain, and gastric distress [11]. It is unclear why antioxidant therapies that have been effective in vitro have not achieved particularly good outcomes in vivo. However, normal ROS production is an integral part of cellular and physiological function; thus, antioxidant therapies can induce damaging reductive cell stress [12].

In addition to ROS production, the activation of c-Jun N-terminal kinases (JNK) and p38 mitogen-activated protein kinase (P38) has been reported in aminoglycoside-treated HCs; and various JNK and P38 inhibitors attenuate aminoglycoside-induced HC death [13–17]. However, JNK and P38 have critical homeostatic functions, meaning that inhibition can have toxic effects in other tissues, such as the liver and spiral ganglion neurons [18, 19]. Therefore, upstream molecules that drive the apoptosis-specific roles of JNK and P38 might represent better targets for ameliorating aminoglycoside-induced HC death. Recently, Tao et al. demonstrated that apoptosis signal-regulating kinase 1 (ASK1) was the only mitogen-activated protein kinase kinase kinase (MAP3K) to have significantly increased RNA expression after aminoglycoside treatment in HCs [20]. ASK1 is activated by redox imbalance and activates downstream MAP kinases, particularly JNK and P38. In addition, multiple ASK1 inhibitors have been developed, with encouraging results in human clinical trials [21]. Therefore, ASK1 inhibition may be a novel strategy for preventing aminoglycoside-induced HC death.

Ask1 is expressed throughout the murine cochlear epithelium, including IHCs and OHCs [22–24] (data may be viewed at https://umgear.org/index.html?layout_id=f64f9c22&gene_symbol=map3k5&gene_symbol_exact_match=0). However, the role of ASK1 as a mediator of aminoglycoside-induced HC death has not been investigated. Furthermore, the role of ASK1 in normal auditory function has not been defined. Therefore, this study aimed to evaluate the importance of ASK1 in the mouse HC by characterising the auditory phenotype of *Ask1*^{−/−} mice and examining whether *Ask1*^{−/−} HCs are resistant to aminoglycoside toxicity. The utility of pharmacologically-mediated ASK1 inhibition was also tested for preventing aminoglycoside-induced HC death.

Methods

Detailed methodology is provided in Supplementary Material 1.

Table 1 The reported prevalence of ototoxic outcomes in humans treated with aminoglycosides. The American Speech Language Hearing Association (ASHA) definition of ototoxicity is described as a hearing threshold shift ≥ 20 dB in one frequency; ≥ 10 dB at any two adjacent frequencies, or loss of response at three consecutive frequencies [25]. However, numerous studies use different definitions of ototoxicity

Aminoglycoside	Prevalence of ototoxic outcomes	Number in sample	Described method for identifying ototoxicity	Definition of ototoxicity	Average duration of therapy	Dosage	Ref
Amikacin	75%	38/51	Audiometry 250–8000 Hz	Hearing was classified as normal (0–20 dB) or impaired (≥ 21 dB) using the Namibian Ministry of Health & Social Services audiogram chart	6–8 months	15 mg/kg/day	[26]
Amikacin	70%	29/41	Audiometry 250–8000 Hz	ASHA 1994 Definition	45 days (range 13–131)	500 mg/day	[27]
Amikacin	62%	270/437	High frequency audiometry or diagnosed by the treating physician	Hearing threshold shift ≥ 15 dB at two or more frequencies or an increase ≥ 20 dB at one frequency; or the absence of usable hearing acquired during or soon after amikacin treatment	167 days (range 105–210)	15 or 25 mg/kg/day	[28]
Amikacin	55%	12/22	Audiometry 250–8000 Hz	Neurosensory hearing loss ≥ 20 dB at any frequency	20 weeks (range 1–43)	75 mg/kg/week	[29]
Amikacin	51%	20/39	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 15 dB at one frequency in one ear or ≥ 10 dB at three frequencies in one ear	20 days (range 4–83)	7.5 mg/kg/12 h	[30]
Amikacin	33%	13/39	Audiometry 250 Hz–20 kHz	ASHA 1994 definition	> 4 days	not defined	[31]
Amikacin	30%	7/23	Audiometry 250–8000 Hz, caloric-evoked nystagmus & cVEMP	Not defined	40 days (range 15–84)	7.5 mg/kg/8 h	[32]
Amikacin	35%	6/17	Audiometry 250 Hz–20 kHz	Hearing threshold shift ≥ 15 dB at two frequencies	8 days $\pm$ 3.3	7.5 mg/kg/12 h	[33]
Amikacin	25%	6/24	Audiogram	ASHA 1994 definition	28 days	15 mg/kg/day	[34]
Amikacin	21%	6/28	Caloric stimulation	No response to caloric test	3 days	15 mg/kg/day	[35]
Amikacin	18%	7/40	Audiometry 250–8000 Hz	Hearing thresholds outside the normal 0–15 dB range for children at 6–8 kHz	5 days $\pm$ 2	15 mg/kg/day	[36]
Amikacin	9%	4/44	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 20 dB at any frequency	138 days (IQR 70–187)	400 mg/day	[37]
Amikacin	7%	4/60	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 15 dB at two or more frequencies	10 days	15 mg/kg/day	[38]
Gentamicin	53%	8/15	Prodromal questioning for vestibular signs & high frequency audiometry	Hearing threshold shift ≥ 15 dB at two frequencies in the same ear or ≥ 10 dB in two frequencies in both ears. Patients also asked about other ototoxic signs including tinnitus, dizziness, or bobbing oscillopsia	8 days $\pm$ 4	4 mg/kg/day	[39]

Table 1 (continued)

Aminoglycoside	Prevalence of ototoxic outcomes	Number in sample	Described method for identifying ototoxicity	Definition of ototoxicity	Average duration of therapy	Dosage	Ref
Gentamycin	34%	116/339	Audiometry 250 Hz–20 kHz	ASHA 1994 definition	> 4 days	Not defined	[31]
Gentamicin	13%	14/106	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 15 dB at both 6 & 8 kHz	5–7 days	80–160 mg/12 h	[40]
Kanamycin	56%	168/302	Audiometry 250–8000 Hz	Hearing was classified using the Namibian Ministry of Health & Social Services audiogram chart. Normal = 0–20 dB. Impaired ≥ 21 dB	6–8 months	15 mg/kg/day	[26]
Kanamycin	42%	14/33	Audiometry 250–8000 Hz	Neurosensory hearing loss ≥ 20 dB at any frequency	14 weeks (range 1–139)	75 mg/kg/week	[29]
Kanamycin	22%	5/23	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 20 dB at any frequency	104 days (range 82–180)	400 mg/day	[37]
Kanamycin	20%	9/42	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 20 dB in one frequency or ≥ 15 dB at any two adjacent frequencies	10 weeks ± 5	Not defined	[41]
Netilmicin	47%	7/15	Prodromal questioning for vestibular signs & high frequency audiometry	Hearing threshold shift ≥ 15 dB at two frequencies in the same ear or ≥ 10 dB in two frequencies in both ears. Patients also asked about other ototoxic signs including tinnitus, dizziness, or bobbing oscillopsia	11 days ± 4	5.5 mg/kg/d	[39]
Netilmicin	4%	3/68	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 15 dB at two frequencies	8 days ± 3	1.7 mg/kg/8 h	[33]
Streptomycin	60%	3/5	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 20 dB in one frequency; ≥ 15 dB at two frequencies	10 weeks ± 6	Not defined	[41]
Streptomycin	19%	6/32	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 20 dB in one frequency	11.5 weeks (range 2–107)	75 mg/kg/week	[29]
Tobramycin	30%	7/23	Electronystagmography with caloric irrigation	Reduced labyrinth excitability	Not defined	Not defined	[42]
Tobramycin	19%	19/102	Audiometry 250–8000 Hz	Hearing threshold shift ≥ 15 dB at two frequencies	8 days ± 3	1.7 mg/kg/8 h	[33]
Tobramycin	18%	5/28	Audiometry 250–20 kHz	ASHA 1994 definition	> 4 days	not defined	[31]

Ref reference, IQR interquartile range, cVEMP cervical vestibular-evoked myogenic potential

Study approval

The Murdoch Children's Research Institute and Sunnybrook Research Institute Animal Ethics Committees approved procedures in project numbers A875, A904, and 21515. The Royal Children's Hospital (RCH) Human Research Ethics Committee approved sputum collection in project number 25054.

Mice

Ask1^{-/-} mice were generated previously [43] and backcrossed for > 12 generations onto the C57BL/6 background. Wild type (WT) C57BL/6 mice were purchased from the Walter and Eliza Hall Institute of Medical Research (Parkville, Australia) and used as experimental controls. CD-1 mice were purchased from Charles River Laboratories (Raleigh, USA).

Acoustic startle response (ASR) and auditory brainstem response (ABR)

ASRs were measured using the SR-LAB system (San Diego Instruments) as described in [44]. ABRs were measured using an evoked potentials workstation and BioSigRP Stimulate/Record System v4.4.1 (Tucker Davis Technologies). Sound pulses were presented to anaesthetised mice, in short bursts (100 µs duration, repeated 512 times), through a free-field magnetic speaker (model FF1, Tucker Davis Technologies) 10 cm from the mouse's left ear. Hearing thresholds were defined as the lowest sound pressure level capable of eliciting a visible ABR.

Tissue collection and analysis

Adult mice were euthanised by anaesthetic overdose and perfused with 10% NBF. Dissected cochleae were decalcified in 10% EDTA (7 days at 4 °C), oriented in 1% agarose in cryomolds (Sakura Finetek, Torrance, CA, USA) and paraffin-embedded. A microtome cut 2-µm sections parallel to the modiolus. Sections were stained with hematoxylin and eosin (H&E).

Neonatal mouse neurosensory epithelium dissection, culture, and processing

See Ogier et al. 2019 protocol [45] for stepwise method. Pups were euthanised by decapitation and cochlear explants were collected for organotypic culture. For *Ask1*^{-/-}-WT comparisons, explants were cultured overnight before fresh media was added containing neomycin or vehicle (DMSO/saline). For ASK1 inhibition

experiments, explants were cultured 3–4 h, before being treated for 16 h with GS-444217 (supplied by Gilead Sciences, San Francisco, CA). Fresh media was added containing GS-444217 and the associated treatment. Explants were fixed and stained (as per Supplementary Material Table 1). For HC quantification, images from the explant base to apex were photo-stitched together and de-identified. Fiji software was used to draw two boxes (0.18 mm × 0.09 mm), which were aligned and overlaid either side of the explant mid-point. HCs were counted using the Fiji cell count tool, including cells with > half the cell body inside the rectangle boundary. The average HC number of the two boxes was recorded for each explant.

Western blot analysis

Protein was extracted from three pooled explants per treatment, producing ~ 1 mg/ml protein per sample. Ten micrograms protein was denatured and separated in a precast Gel (Bio-Rad Cat#4,561,093). Protein was transferred onto a 0.45 µm pore PVDF membrane (Immobilon-P, Cat#IPVH00010). Antibodies were incubated as per Supplementary Material Table 1. Relative quantification of steady state protein levels was performed by first normalising to the loading control, and then to a non-treated negative control within each blot.

Antibiotic minimum inhibitory concentration assay

Antibiotic efficacy was tested against a blood isolate *Pseudomonas aeruginosa* reference strain (American type culture collection, 27853-provided by the RCH Department of Microbiology) and two clinical isolates (0307 and 0315 provided by RCH Respiratory and Sleep Medicine, having been collected by the Australian Respiratory Early Surveillance Team for Cystic Fibrosis and isolated by RCH pathology). A 96-well plate containing serial 1:2 dilutions of amikacin, tobramycin or neomycin and GS-444217 was inoculated with *P. aeruginosa* and incubated at 37 °C for 16 h. The minimum inhibitory concentration (MIC) was defined as the amount of antibiotic required to prevent bacterial metabolism of resazurin, as measured by fluorescence (540 nm excitation and 580 nm emission) on an Infinite M200 Pro plate reader (Tecan life Sciences).

Statistics

ABR and ASR data was compared between groups for each frequency/volume tested using unpaired *T* tests (with the Holm Sidak correction for multiple comparisons). Protein




Fig. 1 Analysis of cochlear morphology and hair cell patterning in *Ask1*^{-/-} mice. **A** Representative H and E stained cochlear mid-modiolar sections from 8-week-old wild type (WT) and *Ask1*^{-/-} mice (upper panels). Scale bar represents 500 μm. Lower panels show higher magnification images of a single mid-turn in the mid-modiolar sections. Scale bar represents 100 μm. SV: scala vestibuli, SM: scala media, St: stria vascularis, OC: organ of Corti, ST: scala tympani. SL: spiral limbus, TM: tectorial membrane OHC: outer hair cells, SG: spiral ganglion (neurons), IHC: inner hair cell, BM: basilar membrane, RM: Reissner's membrane. *n* = 3 mice per genotype. **B** Representative confocal images of WT and *Ask1*^{-/-} neonatal (P4)

cochlear explants that were cultured overnight. Red = Myosin VIIa stain used to identify hair cells and Blue = nuclear DAPI counterstain. The single row of inner hair cells (yellow arrowhead), and three rows of outer hair cells (square brackets) are clearly delineated. Scale bars = 70 μm. **C** Phalloidin staining of P3 explants (green) shows stereocilia bundles with graded changes in length and width, from apex (upper panels) to base (lower panels). Scale bar = 10 μm. **D** Phalloidin staining of the upper-mid region of an *Ask1*^{-/-} explant, counterstained with DAPI (blue) also demonstrates hair cell patterning in the *Ask1*^{-/-} explant. Scale bar = 70 μm

levels were compared using a standard two-way ANOVA with Sidak's multiple comparison test. A standard two-way ANOVA was used to identify changes in MICs and post hoc *T* tests were performed using the two-stage step-up false discovery method of Benjamini, Krieger, and Yekutieli. These analyses were performed using GraphPad prism (version 7.0a for Mac). HC counts were analysed with a three-way analysis of variance, before pairwise Fisher individual tests of the differences of means were performed to ascertain *p* values for strain/treatment. This analysis was performed in Minitab software (version 17 for Windows) under the guidance of Dr. Sue Finch, Melbourne University Statistical Consulting Platform.

Results

Ask1^{-/-} cochlear morphology and HCs appear normal


No gross deformities were noted during dissection, nor in sectioned *Ask1*^{-/-} cochleae, compared to WT controls

(Fig. 1A). Myosin VIIa-staining of cochlear explants dissected from neonatal (P4) mice showed HCs in typical formation, in both WT and *Ask1*^{-/-} explants (Fig. 1B). Phalloidin staining of P3 explants showed stereocilia on the apical HC surfaces of both WT and *Ask1*^{-/-} explants (Fig. 1C).

Functional assessment of hearing in *Ask1*^{-/-} mice

The acoustic startle response (ASR) of male *Ask1*^{-/-} mice was significantly higher than that of WT controls, suggesting that male *Ask1*^{-/-} mice are acoustically hypersensitive (Fig. 2A). A similar trend was present in the data from female *Ask1*^{-/-} mice, although this did not reach statistical significance. As factors unrelated to hearing, such as muscle strength, emotional status, or memory function can contribute to the ASR [46, 47], the auditory brainstem response (ABR) was performed to assess hearing in the *Ask1*^{-/-} strain. ABR testing showed that there was no difference between *Ask1*^{-/-} and WT hearing thresholds when measured between 4 and 32 kHz at 4, 10, and 24 weeks of age (Fig. 2B).

Fig. 2 The *Ask1*^{-/-} acoustic startle response and auditory brainstem response. **A** *Ask1*^{-/-} mice (red) tended to have a stronger acoustic startle response than wild type (WT) controls (black). This difference was statistically significant in the male cohort, as detected using multiple unpaired *T* tests, * indicates $p < 0.05$, ** indicates $p < 0.01$, *** indicates $p < 0.001$. Error bars represent SEM. **B** The auditory brainstem response thresholds of *Ask1*^{-/-} (red) and WT (black) mice. There was no significant difference between the average hearing thresholds of *Ask1*^{-/-} and WT mice at 4, 10, and 24 weeks of age. Age-related, high-frequency hearing loss was evident in both *Ask1*^{-/-} and WT mice at 24 weeks of age. F=female, M=male, *n*=sample size. Error bars = S.D



Ask1^{-/-} HCs are resistant to neomycin-induced cell death

Cochlear explants were cultured overnight before the addition of 1 mM neomycin or vehicle (DMSO). Notable OHC death (as indicated by positive TUNEL staining) occurred 20 h after treatment commenced (Fig. 3A). After 45 h, there was a notable loss of Myosin VIIa-positive HCs and TUNEL staining was prevalent. By 69 h, neomycin caused near-complete loss of Myosin VIIa positive HCs. In comparison, *Ask1*^{-/-} explants showed a markedly different response to neomycin treatment. There was no observable HC TUNEL stain at the 20 h time point, very little at the 45 h time point and none at the 69 h time point (Fig. 3A). Furthermore, the nuclear compartment of remaining HCs appeared less fragmented at the 20- and 45 h time points in the *Ask1*^{-/-} group when compared to time-matched controls. However, at the 69 h time point, the nuclei of Myosin VIIa-positive HCs were significantly condensed or fragmented in the *Ask1*^{-/-} explants (Fig. 3A). These qualitative observations suggested that HC death is delayed in neomycin-treated *Ask1*^{-/-} explants. This observation also indicated that TUNEL staining was not the most suitable means to assess hair cell death, because hair cells that were lost were not always TUNEL-positive at the time points captured. In contrast, Myosin VIIa immunohistochemistry provided robust and specific hair cell labelling. As a result, the subsequent methodology for quantifying hair cell survival was based on Myosin-VIIa staining.

To quantify HC survival, we determined the number of Myosin VIIa positive cells in two 180 $\mu\text{m} \times 90 \mu\text{m}$ fields of view in the cochlear mid-turn. Over a time-course of 3 days, there was no significant difference between the HC counts in WT and *Ask1*^{-/-} explants that had been treated with vehicle only ($p = 0.4$ (IHC), 0.7 (OHC), two-way ANOVA) (Fig. 3B). In comparison, significant genotype dependant differences were observed after neomycin treatment. At the 24 h time point, $77\% \pm 3\%$ of IHCs remained in neomycin-treated WT explants, which was significantly less than the neomycin-treated *Ask1*^{-/-} explants ($91\% \pm 2\%$) (mean $\pm$ SEM, $p = 0.006$) (Fig. 3B, C). In contrast, there was no significant difference between WT and *Ask1*^{-/-} IHC counts at the 48- and 72 h time points ($p = 0.8$ and 0.7 respectively) (Fig. 3B, C). Neomycin-induced OHC death was more pronounced than IHC death in both WT and *Ask1*^{-/-} explants. However, *Ask1*^{-/-} OHCs showed resistance to neomycin toxicity, as evidenced by a significantly slower rate of loss when compared to neomycin-treated WT OHCs (Fig. 3B). After 24 h of neomycin treatment, only $52\% \pm 7\%$ of WT OHCs remained compared with $77\% \pm 6\%$ of *Ask1*^{-/-} OHCs ($p = 0.02$). The difference was not significant at the 48 h time point, with $19\% \pm 4\%$ of WT OHCs persisting compared to $26\% \pm 3\%$ *Ask1*^{-/-} OHCs ($p = 0.2$). After 3 days of neomycin treatment, only $3\% \pm 1\%$ of the OHCs remained in WT explants compared to $16\% \pm 2\%$ in the *Ask1*^{-/-} explants ($p = 0.0002$) (Fig. 3C).




Fig. 3 Effect of *Ask1* knockout on neomycin-induced hair cell death. **A** Representative images of wild type (WT) P3 cochlear explants (left) compared with *Ask1*^{-/-} cochlear explants (right) treated for 20, 45, or 69 h with 1 mM of neomycin. Green=TUNEL stain (dying cells), blue=DAPI (nuclei), red=Myosin VIIa (hair cells). Images were collected from the mid-turn of each explant. Scale bar=50 μ m. **B** Average number of Myosin VIIa-labelled inner and outer hair cells after 24, 48, or 72 h treatment with either vehicle (DMSO) or 1 mM

neomycin. The *n* values for 24, 48, or 72 h respectively are: WT DMSO *n*=7, 9, 7; *Ask1*^{-/-} DMSO *n*=6, 8, 7; WT neomycin *n*=8, 7, 6 and *Ask1*^{-/-} neomycin *n*=7, 5, 7. Mean $\pm$ SEM shown (**p*<0.05, ***p*<0.01 per fisher individual means test). **C** Hair cell counts presented as percentage survival based on average hair cell counts in the DMSO control group. Mean $\pm$ SEM shown (**p*<0.05, ***p*<0.01, ****p*<0.001, n.s.=not significant as per a standard unpaired *T* test)

ASK1 inhibition protects WT HCs from neomycin toxicity


Having demonstrated that a genetic-mediated reduction in ASK1 affords protection against neomycin-induced HC death in vitro, we hypothesised that a small-molecule inhibitor of ASK1 (GS-444217) would also protect WT (C57BL/6) HCs against neomycin toxicity in vitro.

To test if treatment with GS-444217 could compromise HC survival, cochlear explants were cultured for 24 h with GS-444217 doses ranging from 0 to 100 μ M. There was no evidence of increased HC death as a result of GS-444217 treatment (one-way ANOVA; OHC counts *p*=0.36, IHC counts *p*=0.27) (Fig. 4A, B, blue line).

Next, we investigated if treatment with GS-444217 could protect against aminoglycoside-induced HC death in vitro. Cochlear explants were pre-treated for 16 h with GS-444217 (0 μ M–100 μ M) or vehicle (DMSO), and then incubated for a further 24 h with the addition of 1 mM neomycin (Fig. 4A, B, orange line). As observed previously (Fig. 3), IHCs

were highly resistant to neomycin treatment, with less than 1% of IHCs lost after 24 h neomycin treatment (Fig. 4A). Overall, there was no significant difference (*p*=0.69) in the number of IHCs in neomycin-treated explants that had been pre-treated with either vehicle (22.7 ± 0.7 , *n*=7) or GS-444217 (23.1 ± 0.5 , *n*=9) at the 24 h time point. In contrast, GS-444217 pre-treatment markedly improved OHC survival in neomycin-treated explants, with concentrations over 1 μ M GS-444217 significantly attenuating OHC death (Fig. 4B, orange line). For explants pre-treated with vehicle (DMSO) before being exposed to 1 mM neomycin, only 38.1 ± 4.8 Myosin VIIa-positive OHCs remained at the 24 h time point. When this number is normalised to untreated controls, a survival rate of 51% is indicated. OHC number increased to 51 ± 2.5 (68% survival) with a pre-treatment of 0.1 μ M GS-444217, and 1 μ M GS-444217 treatment resulted in 63 ± 2.5 OHCs surviving (92% survival). At a concentration of 100 μ M GS-444217 pre-treatment, 68 ± 1.4 OHCs survived, representing 95% cell survival when compared to the DMSO treated controls (Fig. 4B).

Fig. 4 Effect of ASK1 inhibitor GS-444217 on hair cell survival in neomycin-treated cochlear explants. Quantitation of Myosin VIIa-positive inner (A) and outer (B) hair cells from explants pre-treated with GS-444217 (0–100 μ M) for 16 h before 24 h incubation with vehicle (DMSO) or 1 mM neomycin. Counts for each explant represent the average of two 180 μ m $\times$ 90 μ m fields of view, taken from the explant mid-turn. *N* values for 0, 0.1, 1, 10, and 100 μ M GS-444217-treated explants respectively = 7, 9, 5, 7, 9 (DMSO) and 8, 6, 7, 9, 8 (neomycin). Mean with SEM shown (***p* < 0.001, n.s. = not statistically significant as per one way ANOVA). C and D The average number of Myosin VIIa-positive inner (C) and outer (D) hair cells for explants that had been pre-treated (16 h) with vehicle (DMSO) (green) or 100 μ M GS-444217 (purple) before the addition of 1 mM neomycin for a 3-day time-course analysis. *N* values for 24-, 48-, and 72 h time points respectively = 8, 5, 5 (DMSO) and 9, 7, 6 (GS-444217). Mean with SEM shown (**p* < 0.05, ****p* < 0.001, n.s. = not statistically significant)



Over a 3-day neomycin treatment period, 100 μ M GS-444217 afforded significant protection for both IHCs and OHCs (Fig. 4C, D). There was no difference in IHC survival at the 24- and 48 h time points. However, after 72 h of neomycin treatment, an average of 10.2 ± 1.7 IHCs were counted in the field of view for vehicle pre-treated explants, compared to 15.3 ± 0.6 in the GS-444217 pre-treated explants (*p* < 0.001). The effect of GS-444217 pre-treatment was more pronounced in the OHCs, protecting against neomycin treatment at every time point tested (Fig. 4D). After 24 h, the average OHC counts for vehicle pre-treated explants was 38.1 ± 4.8 compared to 68.2 ± 1.3 in the GS-444217 pre-treated explants (*p* < 0.001). At 48 h, only 25 ± 2.2 OHCs persisted in the vehicle pre-treated explants compared to 41.8 ± 5.9 in the GS-444217 pre-treated group (*p* = 0.04) and after 72 h neomycin treatment, 16.2 ± 1.9 OHCs remained in the vehicle group, compared to 32.1 ± 4.2 in the GS-444217 group (*p* = 0.01).

Protective effect of GS-444217 in cochlear explants

To investigate how GS-444217 reduces neomycin-induced hair cell death, we performed immunohistochemistry and western blot analysis. As previously observed in our ASK1 genetic knockout experiments (Fig. 3), ASK1 inhibition using GS-444217 limited canonical apoptosis (indicated by TUNEL staining) (Fig. 5A). Immunohistochemistry also showed that GS-444217 pre-treatment limited neomycin-induced ASK1 phosphorylation in cochlear hair cells (Fig. 5B). Western blot analysis of WT cochlear explants that were pre-treated with GS-444217 and then cultured for 24 h with either vehicle (DMSO) or 1 mM neomycin indicated a significant reduction of p-P38 when explants were pre-treated with GS-444217 in DMSO co-treated culture conditions (Fig. 5C). A similar trend of reduced p-P38 in GS-444217 pre-treated explants was observed in explants cultured with neomycin. Likewise,




Fig. 5 Molecular effects of GS-444217 treatment in cochlear explants. **A** TUNEL stained, wild type (WT) CD-1 cochlear explants (P3) that had been pre-treated with DMSO (left) or 10 μ M GS-444217 (right), and subsequently treated with 1 mM neomycin for 24 h. White=TUNEL (dying cells), green=phalloidin (highlighting hair cells), red=SOX2 (support cells), blue=DAPI (nuclei). Scale bar=40 μ m. **B** P3 WT explants that had been pre-treated with DMSO or 10 μ M GS-444217 before receiving 1 mM neomycin treatment (or saline control) labelled with p-ASK1 (green), phalloidin (red), and SOX2 (yellow). Scale bar=20 μ m. **C** Representative western blot stained for p-P38 and loading control (GAPDH) followed by protein quantification ($n=3$). Note: the faint band above GAPDH is p-P38. **D** Representative western blot stained for p-JNK1, 2 and 3, and loading control (GAPDH); followed by protein quantification ($n=3$). JNK 1, 2 and 3 are present in two isoforms (p54 and p46). Each sample contains protein extracted from three pooled explants that had been pre-treated with either DMSO or 100 μ M GS-444217 and subsequently co-treated with either DMSO or 1 mM neomycin (neo) for 24 h. Relative protein levels in DMSO and neomycin-treated samples were calculated by first normalising to the loading control and then to the correlated non-treated control (pre-treatment $\rightarrow$ none). Error bars=SEM, $*=p<0.05$, $**=p<0.01$, as detected using a standard two-way ANOVA. **E** Support cells in cochlear explants treated with 1 mM neomycin for 12 h are positive for p-P38; however, this signal appears reduced in explants pretreated with 10 μ M GS-444217. **F** Cochlear explants treated with 1 mM neomycin for 4 h and labelled with a p-JNK antibody indicate that 10 μ M GS-444217 pre-treatment attenuates pro-apoptosis JNK phosphorylation in cochlear hair cells. For E and F, red=p-P38/p-JNK, green=phalloidin (hair cells), yellow=SOX2 (support cells), blue=DAPI, and scale bar=20 μ m

the p-JNK signal tended to be lower in explants that had been pre-treated with GS-444217, for both DMSO and neomycin-treated explants; however, this was not statistically significant. (Fig. 5D). We then performed a time course experiment to elucidate the impact of GS-444217 pre-treatment on JNK and P38 phosphorylation in cochlear explants, from 1 to 24 h post neomycin treatment (Supplementary Figs. 1–3). P38 phosphorylation was most notable in the supporting and epithelial cells of the cochlear explant (Fig. 5E), whereas the strongest p-JNK signal was observed in hair cells 4 h post-neomycin treatment (Fig. 5F). A faint p-JNK signal was also detected in the supporting cells of neomycin-treated cochlear explants (Supplementary Fig. 3). Notably, a strong p-JNK signal was present in the axons of spiral ganglia in all treatment groups, correlating with previous observations that p-JNK has a homeostatic role for axonal development and maintenance (Supplementary Fig. 3) [19, 48, 49].

GS-444217 does not impair antibiotic efficacy against *Pseudomonas aeruginosa* isolates

To evaluate the possibility that GS-444217 could have an off-target effect upon antibiotic action, the minimum inhibitory concentration (MIC) of amikacin, tobramycin, and neomycin against *Pseudomonas aeruginosa* (*P. aeruginosa*) was

determined. *P. aeruginosa* is the most common cause of chronic lung infections in individuals with cystic fibrosis and these individuals are particularly susceptible to aminoglycoside-induced hearing loss, due to long-term aminoglycoside treatment [50]. One reference strain (ATTC 27853) and two clinical isolates (0307 and 0315) were utilised. Tobramycin and amikacin were tested because they are the most clinically utilised aminoglycosides for *P. aeruginosa* treatment. Neomycin was also tested as an aminoglycoside frequently used in the laboratory. The broth dilution test demonstrated that GS-444217 co-treatment did not significantly change the minimum antibiotic concentration required for any antibiotic tested to inhibit resazurin metabolism in all three *P. aeruginosa* strains (Fig. 6).

Discussion

This study utilised *Ask1*^{-/-} mice and a small-molecule inhibitor of ASK1 (GS-444217) to test if the downregulation of ASK1 attenuates aminoglycoside-induced HC death. Both genetic and pharmacological approaches demonstrated that ASK1 has an important role in the process of HC death and indicated that ASK1 inhibition could limit aminoglycoside ototoxicity.

Prior to this work, the effect of *Ask1* knockout on auditory function had not been investigated. We used a combination of histology, immunohistochemistry, and functional ABR testing to demonstrate that *Ask1* knockout does not compromise the peripheral auditory structures or hearing thresholds of mice. However, male *Ask1*^{-/-} mice presented with a hypersensitive startle response when compared to WT controls, and a similar trend was observed in the female cohort. It is difficult to predict what the underlying cause of the unusually strong ASR might be, because auditory signal integration and efferent control is not well understood [51]. High ASR's generally indicate neural processing dysfunction in an auditory or psychiatric disorder [52], whilst factors such as muscle strength, emotional status, and memory function can also affect the ASR [46, 47]. Notably, abnormal behaviour in *Ask1*^{-/-} mice has been previously reported, including hyperactivity, enhanced motor coordination, and significantly increased dopaminergic transmission [53]. ASK1 deficiency has also been implicated with impaired sensory gating in individuals with schizophrenia [54] and an ASK1 polymorphism is associated with reduced cognitive empathy in men [55]. Combined, these observations suggest that ASK1 may play a role in neuronal signalling. Whilst this has not yet been directly investigated, *Ask1*^{-/-} mice could prove useful for further exploration of neuronal development and signal processing mechanisms.

The major aim of this study was to investigate the potential role of ASK1 in aminoglycoside-induced HC death. Analysis






Fig. 6 The effect of GS-444217 on the minimum inhibitory concentration required of tobramycin, amikacin, or neomycin to prevent *Pseudomonas aeruginosa* metabolism of resazurin. MIC's were calculated using the broth dilution test for **A** tobramycin, **B** amikacin and **C** neomycin. n =three broth dilution plates per isolate for each antibiotic, with each plate containing two replicates for each GS-444217 concentration. Error bars=SEM. Note, no error bars indicate that calculated MIC was the same for all three plates

of *Ask1*^{-/-} cochlear explants demonstrated that *Ask1* deficiency significantly attenuates neomycin-induced OHC death. *Ask1* deficiency also afforded some protection against neomycin-induced IHC death; however, this was less pronounced. Subsequent experiments using GS-444217 produced results that correlated with the genetic ablation data. However, HC survival appeared slightly higher in the pharmacological data. The main methodological difference between these independent experiments was the addition of DMSO, used as a vehicle for GS-444217. DMSO is a potent antioxidant that has previously been shown to increase hair cell survival [56–58]. Therefore, the DMSO used in the GS-444217 pre-treatment/control may account for any improvement of HC survival during pharmacological experiments. Overall, GS-444217 pre-treatment resulted in significantly more OHCs surviving 3 days of neomycin treatment, when compared with DMSO pre-treated controls. However, neither genetic knockout nor pharmacological inhibition of ASK1 completely attenuated HC death. This suggests that alternate mechanisms, such as MAPK independent caspase activation, may be removing HCs. Alternatively, damaged HCs can be phagocytosed by cochlear-resident macrophages or supporting cells [59, 60]. Western blot analysis indicated that P38 and JNK phosphorylation occurred in GS-444217-treated explants, which correlates with previous studies that utilised *Ask1*^{-/-} mice and ASK1 inhibitors in alternate disease models [43, 61, 62]. Therefore, it is likely that ASK1 independent mechanisms are able to activate the P38 and JNK pathways in cochlear explants. Nevertheless, the increased HC survival observed in GS-444217-neomycin-treated explants was significant, especially given the non-physiological conditions in which cochlear explants are cultured. In particular, the experimental dose of 1 mM neomycin—applied directly to the HCs in vitro—is unlikely to represent the concentration of aminoglycoside found in vivo in cochlear endolymph. This experimental dose is used in vitro to achieve clear results in a limited experimental timeframe, because optimal HC survival is less than one week in vitro [45]. However, a dose achieving cochlear levels of 1 mM neomycin would not be considered safe for use in humans. Likewise, other clinically utilised aminoglycosides do not reach such high concentrations in vivo. For example, a study of 113 individuals receiving amikacin over a 2-week period demonstrated that average peak plasma concentrations did not exceed 17 μ M amikacin [63]. Moreover, the stria vascularis acts as an important blood-barrier in vivo, limiting the amount of aminoglycoside entering the

endolymph. Kinetic studies in rats have shown that a gentamycin plasma level of 13–14 μ M achieves only 3.1 μ M in the perilymph and 2.5 μ M in the endolymph [64]. Similar results have been observed in the guinea pig, with intravenous gentamycin (300 mg/kg) achieving a peak plasma concentration of 1.1 mM, but only 0.3 mM in the cochlear lymph 3 h after treatment [65]. Therefore, the otoprotective effect of GS-444217 may be stronger in vivo, where HCs are likely to be exposed to significantly lower aminoglycoside concentrations than those used in this in vitro study.

To further investigate the utility of pharmacological inhibition of ASK1 as a protective strategy against aminoglycoside ototoxicity, we tested whether GS-444217 altered the efficacy of aminoglycosides against *P. aeruginosa* in vitro. Notably, these data indicated that 100 μ M GS-444217 did not impair antibiotic efficacy, whereas 1 μ M GS-444217 significantly attenuated neomycin-induced HC death. In combination, these results suggest that GS-444217 could be used to prevent aminoglycoside-induced HC death without impacting primary aminoglycoside care. Whilst this must be assessed in vivo, the promising safety of ASK1 inhibitors taken orally in clinical trials, combined with the observation that GS-444217 does not affect aminoglycoside antibiotic efficacy in vitro, implies that ASK1 inhibition could be applied as an otoprotective strategy in the clinic. Further studies are now needed to confirm that GS-444217 and other promising ASK1 inhibitors do not impair antibiotic efficacy against common infections, such as Group *B streptococcus*, *E. coli*, *Staphylococcus aureus*, or Enterobacteriaceae infection. These organisms often cause sepsis in neonates and subsequent aminoglycoside treatment is the greatest risk factor for these newborns developing hearing loss [66–68].

Collectively, our data provide compelling evidence that ASK1 inhibition may be a valid strategy for mitigating aminoglycoside-induced hearing loss in humans. Whilst previous studies have demonstrated the safety of ASK1 inhibition in human clinical trials [21], strong in vivo efficacy data is required to provide the evidence base for clinical testing of ASK1 inhibition in aminoglycoside-treated individuals. In particular, the inhibitor dosing schedule required to achieve meaningful auditory protection must be determined. Based on the safety results of human clinical trials to date, we anticipate the minimum dose of an ASK1 inhibitor will have no effect on the innate immune response; however, this needs to be fully evaluated in vivo. In this study, we have demonstrated that 1 μ M of GS-444217 significantly attenuates HC death caused by 1 mM neomycin treatment. However, a trend of improved HC survival was also achieved using only 0.1 μ M GS-444217. It is difficult to predict the exact GS-444217 dosing regimen that will be required to achieve similar cochlear concentrations in vivo; however, previous studies have achieved GS-444217 plasma concentrations markedly

higher than 1 μM . For example, a single oral dose of 50 mg/kg GS-444217 resulted in plasma levels of 92.8 mM in mice [69]. In rats, a single oral dose of 30 mg/kg, achieved peak plasma concentrations approaching 100 μM , although GS-444217 plasma levels declined to approximately 0.1 μM after 24 h [70]. This indicates that twice daily GS-444217 dosing may be beneficial. Other ASK1 inhibitors have also been tested in vivo, with 30 mg/kg of GS-459679 achieving plasma concentrations of approximately 6 μM in mice, 6.5 h after administration [71]. Unfortunately, a conspicuous limitation for in vivo testing of ASK1 inhibition as an otoprotective strategy is that mice appear to be intrinsically resistant to aminoglycoside-induced HC death [72]. Therefore, additional models are required to generate the necessary pre-clinical data. The pig may be appropriate, as the porcine metabolic rate, immune system, cochlea, and auditory range closely mimic that of humans [73, 74]. In addition, swine models of cystic fibrosis exist that may be valuable for studying the progression of infection and the efficacy of aminoglycoside antibiotics when an adjuvant ASK1 inhibitor is used [75]. A porcine model could also provide information regarding the benefits of ASK1 inhibition in regard to other aminoglycoside toxicities, such as aminoglycoside nephron and neurotoxicity.

This work provides a strong foundation to justify the development of pre-clinical models that may lead to the development of an adjuvant otoprotective therapy. Such a therapy would have far-reaching implications, as aminoglycoside ototoxicity is a significant health issue, not only for those directly affected, but also clinical health care providers and the economy in general. Avoiding the distressing and lifelong co-morbidities of acquired hearing loss, such as loneliness, impaired mobility, mental fatigue, cognitive decline, and increased mortality risk, is critically important for the health of an individual. From an economic perspective, mitigating aminoglycoside ototoxicity will reduce the financial burden of acquired hearing loss within the national health, education, and welfare systems. In the case of critical healthcare, the prevention of aminoglycoside ototoxicity may also improve the utility of aminoglycoside antibiotics. At present, clinicians must consider the risk of permanent hearing loss against the risk to life when prescribing an aminoglycoside treatment. However, reducing ototoxic outcomes would ease the burden experienced by clinicians during this decision-making process and potentially allow for the wider application of aminoglycoside therapy.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1007/s00109-022-02188-1>.

Acknowledgements The authors thank the AREST CF participants, and RCH pathology, animal house staff, Matthew Burton, Dr Sue

Finch, and Rosemary Carzino for providing support and/or services used in this project.

Author contribution Jacqueline Ogier: conceptualisation, data curation, formal analysis, funding acquisition, investigation, project administration, methodology, visualisation, writing (original draft, review, and editing). Yujing Gao: conceptualisation, data curation, investigation, methodology, and draft review. Eileen Dunne: conceptualisation, methodology, resources, and draft review. Michael Wilson: conceptualisation and draft review. Gregory H Tesch: conceptualisation, resources, and draft review. David J Nikolic Paterson: conceptualisation, resources, and draft review. Alain Dabdoub: methodology, funding, and resources. Rachel Burt: conceptualisation, methodology, supervision, funding acquisition, resources, and draft review. Bryony Nayagam: conceptualisation, methodology, supervision, and draft review. Paul Lockhart: conceptualisation, methodology, supervision, funding acquisition, resources, and draft review.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions. The authors are supported by the Garnett Passe and Rodney Williams Memorial Foundation (PhD Research scholarship to JMO; Research Fellowship to BAN), the Vincent Chiodo Foundation (PIL), and the Koerner Foundation (AD). Additional infrastructure funding to the Murdoch Children's Research Institute was provided by the Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme and the Victorian Government's Operational Infrastructure Support Program.

Data availability Important data generated or analysed during this study is included in this published article. Further information is available from the corresponding author on reasonable request.

Declarations

Ethics approvals, patient consent, and consent to publish The Murdoch Children's Research Institute Animal Ethics Committee approved mouse procedures in project numbers A875 and A904, in compliance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013. The Sunnybrook Research Institute (SRI) Animal Care Committee approved mouse procedures in protocol number 21515, conforming with Canadian Council on Animal Care requirements. The Royal Children's Hospital (RCH) Human Research Ethics Committee approved the collection of sputum specimens in project number 25054. Clinical specimens were collected in accordance with the National Health and Medical Research Council's Statement on Ethical Conduct in Human Research, 2007 (2018 Update) and the Australian Code for the Responsible Conduct of Research, 2018. Written approval for collection, research, and publication using participant sputum samples was given by the parents of participants (signed informed consent forms).

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended

use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Grill MF, Maganti RK (2011) Neurotoxic effects associated with antibiotic use: management considerations. *Br J Clin Pharmacol* 72:381–393. <https://doi.org/10.1111/j.1365-2125.2011.03991.x>
- HayMcCutcheon JM, Reed PE, Cheimariou S (2018) Positive social interaction and hearing loss in older adults living in rural and urban communities. *J Speech Lang Hear Res* 61:2138–2145. https://doi.org/10.1044/2018_JSLHR-H-17-0485
- Dammeyer J, Crowe K, Marschark M, Rosica M (2019) Work and employment characteristics of deaf and hard-of-hearing adults. *J Deaf Stud Deaf Educ* 24:386–395. <https://doi.org/10.1093/deafed/enz018>
- Rajendran V, Roy FG (2010) Comparison of health related quality of life of primary school deaf children with and without motor impairment. *Ital J Pediatr* 36:75. <https://doi.org/10.1186/1824-7288-36-75>
- Huth ME, Han K-H, Sotoudeh K et al (2015) Designer aminoglycosides prevent cochlear hair cell loss and hearing loss. *J Clin Invest* 125:583–592
- Wang Q, Steyger PS (2009) Trafficking of systemic fluorescent gentamicin into the cochlea and hair cells. *J Assoc Res Otolaryngol* 10:205–219. <https://doi.org/10.1007/s10162-009-0160-4>
- Cabañas MJ, Vázquez D, Modolell J (1978) Inhibition of ribosomal translocation by aminoglycoside antibiotics. *Biochem Biophys Res Commun* 83:991–997. [https://doi.org/10.1016/0006-291x\(78\)91493-6](https://doi.org/10.1016/0006-291x(78)91493-6)
- Clerici WJ, Hensley K, DiMartino DL, Butterfield DA (1996) Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. *Hear Res* 98:116–124
- Hirose K, Hockenbery DM, Rubel EW (1997) Reactive oxygen species in chick hair cells after gentamicin exposure in vitro. *Hear Res* 104:1–14. [https://doi.org/10.1016/s0378-5955\(96\)00169-4](https://doi.org/10.1016/s0378-5955(96)00169-4)
- Sha SH, Schacht J (1999) Stimulation of free radical formation by aminoglycoside antibiotics. *Hear Res* 128:112–118. [https://doi.org/10.1016/s0378-5955\(98\)00200-7](https://doi.org/10.1016/s0378-5955(98)00200-7)
- Hammill TL, Campbell KC (2018) Protection for medication-induced hearing loss: the state of the science. *Int J Audiol* 57:S67–S75. <https://doi.org/10.1080/14992027.2018.1455114>
- Villanueva C, Kross RD (2012) Antioxidant-induced stress. *Int J Mol Sci* 13:2091–2109. <https://doi.org/10.3390/ijms13022091>
- Bas E, Van De Water TR, Gupta C et al (2012) Efficacy of three drugs for protecting against gentamicin-induced hair cell and hearing losses. *Br J Pharmacol* 166:1888–1904. <https://doi.org/10.1111/j.1476-5381.2012.01890.x>
- Ylikoski J, Xing-Qun L, Virkkala J, Pirvola U (2002) Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. *Hear Res* 163:71–81. [https://doi.org/10.1016/s0378-5955\(01\)00380-x](https://doi.org/10.1016/s0378-5955(01)00380-x)
- Pirvola U, Xing-Qun L, Virkkala J et al (2000) Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. *J Neurosci* 20:43–50. <https://doi.org/10.1523/JNEUROSCI.20-01-00043.2000>
- Francis SP, Katz J, Fanning KD et al (2013) A novel role of cytosolic protein synthesis inhibition in aminoglycoside ototoxicity. *J Neurosci* 33:3079–3093. <https://doi.org/10.1523/JNEUROSCI.3430-12.2013>
- Sugahara K, Rubel EW, Cunningham LL (2006) JNK signaling in neomycin-induced vestibular hair cell death. *Hear Res* 221:128–135. <https://doi.org/10.1016/j.heares.2006.08.009>
- Tesch GH, Ma FY, Nikolic-Paterson DJ (2016) ASK1: a new therapeutic target for kidney disease. *Am J Physiol Renal Physiol* 311:F373–F381. <https://doi.org/10.1152/ajprenal.00208.2016>
- Bodmer D, Gloddek B, Ryan AF et al (2002) Inhibition of the c-Jun N-terminal kinase signaling pathway influences neurite outgrowth of spiral ganglion neurons in vitro. *Laryngoscope* 112:2057–2061. <https://doi.org/10.1097/00005537-200211000-00028>
- Tao L, Segil N (2015) Early transcriptional response to aminoglycoside antibiotic suggests alternate pathways leading to apoptosis in sensory hair cells in the mouse inner ear. *Front Cell Neurosci* 9:190. <https://doi.org/10.3389/fncel.2015.00190>
- Ogier JM, Nayagam BA, Lockhart PJ (2020) ASK1 inhibition: a therapeutic strategy with multi-system benefits. *J Mol Med (Berl)* 98:335–348. <https://doi.org/10.1007/s00109-020-01878-y>
- Elkon R, Milon B, Morrison L et al (2015) RFX transcription factors are essential for hearing in mice. *Nat Commun* 6:8549
- Cai T, Jen H-I, Kang H et al (2015) Characterization of the transcriptome of nascent hair cells and identification of direct targets of the Atoh1 Transcription Factor. *J Neurosci* 35:5870
- Liu H, Chen L, Giffen KP et al (2018) Cell-specific transcriptome analysis shows that adult pillar and Deiters' cells express genes encoding machinery for specializations of cochlear hair cells. *Front Mol Neurosci* 11:356. <https://doi.org/10.3389/fnmol.2018.00356>
- American Speech-Language-Hearing Association (1994) Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. Available from www.asha.org/policy (<https://doi.org/10.1044/policy.GL1994-00003>)
- Sagwa EL, Ruswa N, Mavhunga F et al (2015) Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. *BMC Pharmacol Toxicol* 16:36
- Javadi MR, Abtahi B, Gholami K et al (2011) The incidence of amikacin ototoxicity in multidrug-resistant tuberculosis patients. *Iran J Pharm Res* 10:905–911
- Modongo C, Sobota RS, Kesenogile B et al (2014) Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss. *BMC Infect Dis* 14:542
- Peloquin CA, Berning SE, Nitta AT et al (2004) Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. *Clin Infect Dis* 38:1538–1544. <https://doi.org/10.1086/420742>
- Axdorph U, Laurell G, Björkholm M (1993) Monitoring of hearing during treatment of leukaemia with special reference to the use of amikacin. *J Intern Med* 233:401–407. <https://doi.org/10.1111/j.1365-2796.1993.tb00691.x>
- Fausti SA, Henry JA, Helt WJ et al (1999) An individualized, sensitive frequency range for early detection of ototoxicity. *Ear Hear* 20:497–505. <https://doi.org/10.1097/00003446-199912000-00005>
- Chen KS, Bach A, Shoup A, Winick NJ (2013) Hearing loss and vestibular dysfunction among children with cancer after receiving aminoglycosides. *Pediatr Blood Cancer* 60:1772–1777. <https://doi.org/10.1002/pbc.24631>
- Gatell JM, Ferran F, Araujo V et al (1987) Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. *Antimicrob Agents Chemother* 31:1383–1387. <https://doi.org/10.1128/aac.31.9.1383>
- Lee H, Sohn YM, Ko JY et al (2017) Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease. *Int J Tuberc Lung Dis* 21:818–824. <https://doi.org/10.5588/ijtld.16.0791>
- Zagólski O (2007) Vestibular system in infants after systemic aminoglycoside therapy. *Int J Pediatr Otorhinolaryngol* 71:1797–1802. <https://doi.org/10.1016/j.ijporl.2007.08.005>
- Forsyth NB, Botha JH, Hadley GP (1997) A comparison of two amikacin dosing regimens in paediatric surgical patients. *Ann*

- Trop Paediatr 17:253–261. <https://doi.org/10.1080/02724936.1997.11747896>
37. van Altena R, Dijkstra JA, van der Meer ME et al (2017) Reduced chance of hearing loss associated with therapeutic drug monitoring of aminoglycosides in the treatment of multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. <https://doi.org/10.1128/AAC.01400-16>
 38. Giamarellou H, Yiallourou K, Petrikos G et al (1991) Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. *J Antimicrob Chemother* 27 Suppl C:73–79. doi: https://doi.org/10.1093/jac/27.suppl_c.73
 39. Tange RA, Dreschler WA, Prins JM et al (1995) Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial. *Clin Otolaryngol Allied Sci* 20:118–123. <https://doi.org/10.1111/j.1365-2273.1995.tb00026.x>
 40. Sha S-H, Qiu J-H, Schacht J (2006) Aspirin to prevent gentamicin-induced hearing loss. *N Engl J Med* 354:1856–1857. <https://doi.org/10.1056/NEJMc053428>
 41. de Jager P, van Altena R (2002) Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. *Int J Tuberc Lung Dis* 6:622–627
 42. Scheenstra RJ, Rijntjes E, Tavy DLJ et al (2009) Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients. *Acta Otolaryngol* 129:4–7. <https://doi.org/10.1080/00016480801968534>
 43. Ma FY, Tesch GH, Nikolic-Paterson DJ (2014) ASK1/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney. *Am J Physiol Renal Physiol* 307:F1263–F1273. <https://doi.org/10.1152/ajprenal.00211.2014>
 44. Ogier JM, Carpinelli MR, Arhatari BD et al (2014) CHD7 deficiency in “Looper”, a new mouse model of CHARGE syndrome, results in ossicle malformation, otosclerosis and hearing impairment. *PLoS ONE* 9:e97559. <https://doi.org/10.1371/journal.pone.0097559>
 45. Ogier JM, Burt RA, Drury HR et al (2019) Organotypic culture of neonatal murine inner ear explants. *Front Cell Neurosci* 13:895. <https://doi.org/10.3389/fncel.2019.00170>
 46. Le Duc J, Fournier P, Hébert S (2016) Modulation of prepulse inhibition and startle reflex by emotions: a comparison between young and older adults. *Front Aging Neurosci* 8:33. <https://doi.org/10.3389/fnagi.2016.00033>
 47. Poli E, Angrilli A (2015) Greater general startle reflex is associated with greater anxiety levels: a correlational study on 111 young women. *Front Behav Neurosci* 9:10. <https://doi.org/10.3389/fnbeh.2015.00010>
 48. Oliva AA, Atkins CM, Copenagle L, Banker GA (2006) Activated c-Jun N-terminal kinase is required for axon formation. *J Neurosci* 26:9462
 49. Murai N, Kirkegaard M, Järleback L et al (2008) Activation of JNK in the inner ear following impulse noise exposure. *J Neurotrauma* 25:72–77. <https://doi.org/10.1089/neu.2007.0346>
 50. Ratjen F, Brockhaus F, Angyalosi G (2009) Aminoglycoside therapy against *Pseudomonas aeruginosa* in cystic fibrosis: a review. *J Cyst Fibros* 8:361–369. <https://doi.org/10.1016/j.jcf.2009.08.004>
 51. Lopez-Poveda EA (2018) Olivocochlear efferents in animals and humans: from anatomy to clinical relevance. *Front Neurol* 9:197. <https://doi.org/10.3389/fneur.2018.00197>
 52. Swerdlow NR, Braff DL, Geyer MA (2016) Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. *J Psychopharmacol* 30:1072–1081. <https://doi.org/10.1177/0269881116661075>
 53. Kumakura K, Nomura H, Toyoda T et al (2010) Hyperactivity in novel environment with increased dopamine and impaired novelty preference in apoptosis signal-regulating kinase 1 (ASK1)-deficient mice. *Neurosci Res* 66:313–320. <https://doi.org/10.1016/j.neures.2009.12.003>
 54. Morris BJ, Pratt JA (2014) Novel treatment strategies for schizophrenia from improved understanding of genetic risk. *Clin Genet* 86:401–411. <https://doi.org/10.1111/cge.12485>
 55. Warrier V, Grasby KL, Uzefovsky F et al (2018) Genome-wide meta-analysis of cognitive empathy: heritability, and correlates with sex, neuropsychiatric conditions and cognition. *Mol Psychiatry* 23:1402–1409
 56. Sanmartín-Suárez C, Soto-Otero R, Sánchez-Sellero I, Méndez-Álvarez E (2011) Antioxidant properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuroprotective antioxidants. *J Pharmacol Toxicol Methods* 63:209–215. <https://doi.org/10.1016/j.vascn.2010.10.004>
 57. Melki SJ, Heddon CM, Frankel JK et al (2010) Pharmacological protection of hearing loss in the mouse model of endolymphatic hydrops. *Laryngoscope* 120:1637–1645. <https://doi.org/10.1002/lary.21018>
 58. Momin SR, Melki SJ, Obokhare JO et al (2011) Hearing preservation in Guinea pigs with long-standing endolymphatic hydrops. *Otol Neurotol* 32:1583–1589. <https://doi.org/10.1097/MAO.0b013e3182382a64>
 59. Hirose K, Rutherford MA, Warchol ME (2017) Two cell populations participate in clearance of damaged hair cells from the sensory epithelia of the inner ear. *Hear Res* 352:70–81. <https://doi.org/10.1016/j.heares.2017.04.006>
 60. Kaur T, Hirose K, Rubel EW, Warchol ME (2015) Macrophage recruitment and epithelial repair following hair cell injury in the mouse utricle. *Front Cell Neurosci* 9:150. <https://doi.org/10.3389/fncel.2015.00150>
 61. Nakagawa H, Maeda S, Hikiba Y et al (2008) Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. *Gastroenterology* 135:1311–1321. <https://doi.org/10.1053/j.gastro.2008.07.006>
 62. Yamaguchi O, Higuchi Y, Hirotani S et al (2003) Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. *Proc Natl Acad Sci USA* 100:15883
 63. Contreras AM, Gamba G, Cortés J et al (1989) Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity. *Antimicrob Agents Chemother* 33:973–976. <https://doi.org/10.1128/aac.33.6.973>
 64. Tran Ba Huy P, Meulemans A, Wassef M et al (1983) Gentamicin persistence in rat endolymph and perilymph after a two-day constant infusion. *Antimicrob Agents Chemother* 23:344–346. <https://doi.org/10.1128/aac.23.2.344>
 65. Hahn H, Salt AN, Schumacher U, Plontke SK (2013) Gentamicin concentration gradients in scala tympani perilymph following systemic applications. *Audiol Neurotol* 18:383–391. <https://doi.org/10.1159/000355283>
 66. Muller-Pebody B, Johnson AP, Heath PT et al (2011) Empirical treatment of neonatal sepsis: are the current guidelines adequate? *Arch Dis Child Fetal Neonatal Ed* 96:F4
 67. Braye K, Foureur M, de Waal K et al (2019) Epidemiology of neonatal early-onset sepsis in a geographically diverse Australian health district 2006–2016. *PLoS ONE* 14:e0214298. <https://doi.org/10.1371/journal.pone.0214298>
 68. Poonual W, Navacharoen N, Kangsanarak J, Namwongprom S (2016) Risk factors for hearing loss in infants under universal hearing screening program in Northern Thailand. *J Multidiscip Healthc* 9:1–5. <https://doi.org/10.2147/JMDH.S92818>
 69. Budas GR, Boehm M, Kojonazarov B et al (2018) ASK1 inhibition halts disease progression in preclinical models of pulmonary arterial hypertension. *Am J Respir Crit Care Med* 197:373–385. <https://doi.org/10.1164/rccm.201703-0502OC>
 70. Liles JT, Corkey BK, Notte GT et al (2018) ASK1 contributes to fibrosis and dysfunction in models of kidney disease. *J Clin Invest* 128:4485–4500. <https://doi.org/10.1172/JCI99768>
 71. Xie Y, Ramachandran A, Breckenridge DG et al (2015) Inhibitor of apoptosis signal-regulating kinase 1 protects against

- acetaminophen-induced liver injury. *Toxicol Appl Pharmacol* 286:1–9. <https://doi.org/10.1016/j.taap.2015.03.019>
72. Ogier JM, Lockhart PJ, Burt RA (2020) Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice. *Hear Res* 386:107870
73. Heffner HE, Heffner RS (2007) Hearing ranges of laboratory animals. *J Am Assoc Lab Anim Sci* 46:20–22
74. Bendixen E, Danielsen M, Larsen K, Bendixen C (2010) Advances in porcine genomics and proteomics—a toolbox for developing the pig as a model organism for molecular biomedical research. *Brief Funct Genomics* 9:208–219. <https://doi.org/10.1093/bfpg/elq004>
75. Welsh MJ, Rogers CS, Stoltz DA et al (2009) Development of a porcine model of cystic fibrosis. *Trans Am Clin Climatol Assoc* 120:149–162